---
schema_version: "secwatch.filing_event.v1"
accession: "0001821586-23-000004"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2023-03-20T23:59:59+00:00"
generated_at: "2026-06-17T23:08:46.869635+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Moonlake reports FY2022 net loss $64.5M; HS trial top-line expected June 2023

## Summary
- Net loss for year ended Dec 31, 2022 was $64.5M vs $53.6M for prior period (March 2021 to Dec 2021).
- Cash, equivalents and short-term marketable debt securities $72.1M at Dec 31, 2022; runway into 2H 2024.
- Phase 2 HS trial top-line results expected around end of June 2023; final readout by Q4 2023.
- Phase 2 PsA trial enrollment on schedule; top-line results anticipated at end of 2023.
- Capital Markets Day set for April 19, 2023 in New York and via webcast.

## SEC filing metadata
- accession: 0001821586-23-000004
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2023-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000182158623000004/0001821586-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000182158623000004/mnlk-20230320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001821586-23-000004
- JSON: https://secwatch.observer/filing/0001821586-23-000004.json
- Plain text: https://secwatch.observer/filing/0001821586-23-000004.txt

## Key facts
- Earnings Releases
  MoonLake Immunotherapeutics reported the fourth quarter and year ended December 31, 2022 results: net income Net loss for the year ended December 31, 2022 was $64.5 million.
  - Period: the fourth quarter and year ended December 31, 2022
  - Net income: Net loss for the year ended December 31, 2022 was $64.5 million
  - Result: reported results
  source text: MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821586/000182158623000004/0001821586-23-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.